儿童低级别胶质瘤的MR成像:在无神经纤维瘤病1型患者中治疗前区分BRAF V600E突变、BRAF融合与野生型肿瘤
该回顾性双中心研究纳入2004至2021年病理确诊的70例儿童低级别胶质瘤患者(BRAF融合30例、BRAF V600E突变19例、野生型21例),由两名神经放射科医生盲法独立评估诊断性MRI参数。结果显示BRAF融合肿瘤更大、占位效应更明显、脑积水更常见且弥漫强化更多;BRAF V600E突变肿瘤更多位于半球、更具浸润性,且是唯一出现扩散受限(定性)和ADC比值更低(定量)的组别。作者结论认为这些影像特征可用于区分三种分子亚型,并有助于靶向治疗时代的术前治疗规划。
要点
- BRAF融合肿瘤较BRAF V600E和野生型更大(P=.0022),占位效应更明显(P=.0053)。
- BRAF融合肿瘤脑积水频率更高(P=.0002),弥漫强化更常见(P<.0001)。
- BRAF V600E突变肿瘤更多位于半球(P<.0001),表现更浸润(P=.0002),是唯一出现扩散受限的组(定性P=.0042),ADC比值更低(P=.003)。
核心结论
- BRAF融合与BRAF V600E突变儿童低级别胶质瘤具有独特影像特征,可通过标准放射学阅片以高读者间一致性相互区分并与野生型区分;在靶向治疗时代,这些特征可能有助于术前治疗规划。
研究设计与样本
- 回顾性双中心研究,纳入2004至2021年病理确诊且分子定义为BRAF融合、BRAF V600E突变或野生型(既非BRAF V600E突变也非BRAF融合)的儿童低级别胶质瘤患者70例(BRAF融合30例、BRAF V600E突变19例、野生型21例);两名神经放射科医生盲法独立评估诊断性MRI参数,分歧经共识解决;采用双变量分析及Dwass-Steel-Critchlow-Fligner法进行三组两两比较;读者间一致性用κ评估。
关键影像表现/征象
- BRAF融合肿瘤较BRAF V600E和野生型肿瘤更大(P=.0022),占位效应更明显(P=.0053)。
- BRAF融合肿瘤脑积水频率更高(P=.0002),弥漫强化更常见(P<.0001)。
- BRAF V600E突变肿瘤更多位于半球(P<.0001),表现更浸润(P=.0002)。
- BRAF V600E突变肿瘤是唯一出现扩散受限的组(定性,P=.0042),定量ADC比值更低(P=.003)。
诊断标准与关键数值
- 总体影像变量读者间一致性为中等(κ=0.75)。
- BRAF融合肿瘤较BRAF V600E和野生型更大(P=.0022)、占位效应更明显(P=.0053)、脑积水频率更高(P=.0002)、弥漫强化更常见(P<.0001)。
- BRAF V600E突变肿瘤更多位于半球(P<.0001)、更浸润(P=.0002)、是唯一出现扩散受限的组(定性P=.0042)且ADC比值更低(P=.003)。
临床应用与阅片要点
- 采用标准放射学阅片评估肿瘤大小、占位效应、脑积水、强化模式、半球位置、浸润性及扩散受限,可高读者间一致性地区分三种分子亚型。
- BRAF融合肿瘤倾向于更大、占位效应更明显、脑积水更常见且弥漫强化更多。
- BRAF V600E突变肿瘤更多位于半球、更浸润,且是唯一出现扩散受限和ADC比值更低的组。
- 在靶向治疗时代,这些特征可能有助于术前治疗规划。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: The prognosis and treatment of pediatric low-grade gliomas is influenced by their molecular subtype. MR imaging remains the mainstay for initial work-up and surgical planning. We aimed to determine the relationship between imaging patterns and molecular subtypes of pediatric low-grade gliomas.
MATERIALS AND METHODS: This was a retrospective bi-institutional study for patients diagnosed from 2004 to 2021 with pathologically confirmed pediatric low-grade gliomas molecularly defined as BRAF fusion, BRAF V600E mutant, or wild-type (which is neither BRAF V600E mutant nor BRAF fusion). Two neuroradiologists, blinded, independently reviewed imaging parameters from diagnostic MRIs, and discrepancies were resolved by consensus. Bivariate analysis was used followed by pair-wise comparison of the Dwass-Steel-Critchlow-Fligner method to compare the 3 molecular subtypes. Interreader agreement was assessed using κ.
RESULTS: We included 70 patients: 30 BRAF fusion, 19 BRAF V600E mutant, and 21 wild-type. There was substantial agreement between the readers for overall imaging variables (κ = 0.75). BRAF fusion tumors compared with BRAF V600E and wild-type tumors were larger (P = .0022), and had a greater mass effect (P = .0053), increased frequency of hydrocephalus (P = .0002), and diffuse enhancement (p <.0001). BRAF V600E mutant tumors were more often hemispheric (P < .0001), appeared more infiltrative (P = .0002), and, though infrequent, were the only group demonstrating diffusion restriction (qualitatively; P = .0042) with a lower ADC ratio (quantitatively) (P = .003).
CONCLUSIONS: BRAF fusion and BRAF V600E mutant pediatric low-grade gliomas have unique imaging features that can be used to differentiate them from each other and wild-type pediatric low-grade glioma using a standard radiology review with high interreader agreement. In the era of targeted therapy, these features can be useful for therapeutic planning before surgery.
引用
- Trasolini, Erker, Cheng, et al. MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of BRAF V600E Mutation, BRAF Fusion, and Wild-Type Tumors in Patients without Neurofibromatosis-1. AJNR Am J Neuroradiol. 2022. PMID: 35863783. doi:10.3174/ajnr.A7574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。